RU97117350A - INTIMA HYPERTROPHY INHIBITOR, OXINDOL DERIVATIVE APPLICATION FOR THE INIMA HYPERTROPHY INHIBITOR INHIBITOR, A COMPOSITION FOR INHIBITING INTIMA HYPERTROPHY, PREVENTION AND TREATMENT HYPERT - Google Patents
INTIMA HYPERTROPHY INHIBITOR, OXINDOL DERIVATIVE APPLICATION FOR THE INIMA HYPERTROPHY INHIBITOR INHIBITOR, A COMPOSITION FOR INHIBITING INTIMA HYPERTROPHY, PREVENTION AND TREATMENT HYPERTInfo
- Publication number
- RU97117350A RU97117350A RU97117350/14A RU97117350A RU97117350A RU 97117350 A RU97117350 A RU 97117350A RU 97117350/14 A RU97117350/14 A RU 97117350/14A RU 97117350 A RU97117350 A RU 97117350A RU 97117350 A RU97117350 A RU 97117350A
- Authority
- RU
- Russia
- Prior art keywords
- group
- substituted
- hydrogen atom
- inhibitor
- amino
- Prior art date
Links
- 206010020880 Hypertrophy Diseases 0.000 title claims 13
- 230000002401 inhibitory effect Effects 0.000 title claims 12
- 239000003112 inhibitor Substances 0.000 title claims 10
- JYGFTBXVXVMTGB-UHFFFAOYSA-N Oxindole Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000003277 amino group Chemical group 0.000 claims 12
- -1 phenylcarbamoyl group Chemical group 0.000 claims 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 11
- 125000003282 alkyl amino group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000004076 pyridyl group Chemical group 0.000 claims 9
- 125000003418 alkyl amino alkoxy group Chemical group 0.000 claims 8
- 239000007787 solid Substances 0.000 claims 5
- 125000004095 oxindolyl group Chemical class N1(C(CC2=CC=CC=C12)=O)* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229910052801 chlorine Chemical group 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (9)
(где R1 представляет атом водорода; фенильную группу, которая может быть замещена низшей алкильной группой, низшей алкокси-группой, низшей алкиламиноалкокси-группой, гидрокси-группой, амино-группой, низшей алкиламино-группой или атомом галогена; или пиридильную группу, которая может быть замещена низшей алкильной группой, низшей алкокси-группой, низшей алкиламиноалкокси-группой, гидрокси-группой, амино-группой, низшей алкиламино-группой, атомом галогена, низшей алкоксикарбонильной группой или карбоксильной группой;
где (а) в случае, когда R1 представляет атом водорода:
R2 представляет фенильную группу, которая может быть замещена гидрокси-группой или низшей алкокси-группой; или пиридильную группу, которая может быть замещена низшей алкильной группой, низшей алкокси-группой, низшей алкиламиноалкокси-группой, гидроксильной группой, амино-группой, низшей алкиламино-группой, атомом галогена, низшей алкоксикарбонильной группой или карбоксильной группой; при этом, каждый из R3 и R4 представляет атом водорода; Х представляет СН; а двойная пунктирная/сплошная линия означает двойную связь;
(b) в случае, когда R1 представляет фенильную группу, которая может быть замещена низшей алкильной группой, низшей алкокси-группой, низшей алкиламиноалкокси-группой, гидрокси-группой, амино-группой, низшей алкиламино-группой или атомом галогена; или пиридильную группу, которая может быть замещена низшей алкильной группой, низшей алкокси-группой, низшей алкиламиноалкокси-группой, гидрокси-группой, амино-группой, низшей алкиламино-группой, атомом галогена, низшей алкоксикарбонильной группой или карбоксильной группой:
R2 представляет фенильную группу, которая может быть замещена низшей алкильной группой, низшей алкокси-группой, низшей алкиламиноалкокси-группой, низшей алкоксикарбонильной группой, карбоксильной группой, гидрокси-группой, аминогруппой, низшей алкиламино-группой или атомом галогена; или пиридильную группу, которая может быть замещена низшей алкильной группой, низшей алкокси-группой, низшей алкиламиноалкокси-группой, гидрокси-группой, амино-группой, низшей алкиламино-группой, атомом галогена, низшей алкоксикарбонильной группой или карбоксильной группой; R3 представляет атом водорода; низшую алкильную группу, которая может быть замещена; бензильную группу, которая может быть замещена; бензолсульфонильную группу, которая может быть замещена; или ацильную группу; R4 представляет атом водорода, низшую алкокси-группу, атом галогена, амино-группу, карбоксильную группу, низшую алкиламино-группу, низшую алкоксикарбонильную группу, фенилкарбамоильную группу, которая может быть замещена, или трифторметильную группу; Х представляет СН или N; n представляет целое число от 0 до 4, включительно, которое обозначает число заместителей; а двойная пунктирная/сплошная линия означает простую или двойную связь.1. An inhibitor of intimal hypertrophy, containing as an active ingredient an oxindole derivative represented by the formula (1) or its salt
(where R 1 represents a hydrogen atom; a phenyl group which may be substituted by a lower alkyl group, a lower alkoxy group, a lower alkylaminoalkoxy group, a hydroxy group, an amino group, a lower alkylamino group or a halogen atom; or a pyridyl group which may be substituted with a lower alkyl group, a lower alkoxy group, a lower alkylaminoalkoxy group, a hydroxy group, an amino group, a lower alkylamino group, a halogen atom, a lower alkoxycarbonyl group or a carboxyl group;
where (a) in the case when R 1 represents a hydrogen atom:
R 2 represents a phenyl group which may be substituted by a hydroxy group or a lower alkoxy group; or a pyridyl group which may be substituted by a lower alkyl group, a lower alkoxy group, a lower alkylaminoalkoxy group, a hydroxyl group, an amino group, a lower alkylamino group, a halogen atom, a lower alkoxycarbonyl group or a carboxyl group; wherein, each of R 3 and R 4 represents a hydrogen atom; X represents CH; a double dashed / solid line means a double bond;
(b) in the case when R 1 represents a phenyl group which may be substituted by a lower alkyl group, a lower alkoxy group, a lower alkylaminoalkoxy group, a hydroxy group, an amino group, a lower alkylamino group or a halogen atom; or a pyridyl group which may be substituted by a lower alkyl group, a lower alkoxy group, a lower alkylaminoalkoxy group, a hydroxy group, an amino group, a lower alkylamino group, a halogen atom, a lower alkoxycarbonyl group or a carboxyl group:
R 2 represents a phenyl group which may be substituted by a lower alkyl group, a lower alkoxy group, a lower alkylaminoalkoxy group, a lower alkoxycarbonyl group, a carboxyl group, a hydroxy group, an amino group, a lower alkylamino group or a halogen atom; or a pyridyl group which may be substituted by a lower alkyl group, a lower alkoxy group, a lower alkylaminoalkoxy group, a hydroxy group, an amino group, a lower alkylamino group, a halogen atom, a lower alkoxycarbonyl group or a carboxyl group; R 3 represents a hydrogen atom; a lower alkyl group which may be substituted; a benzyl group which may be substituted; a benzenesulfonyl group which may be substituted; or an acyl group; R 4 represents a hydrogen atom, a lower alkoxy group, a halogen atom, an amino group, a carboxyl group, a lower alkylamino group, a lower alkoxycarbonyl group, a phenylcarbamoyl group which may be substituted, or a trifluoromethyl group; X is CH or N; n is an integer from 0 to 4, inclusive, which represents the number of substituents; and a double dashed / solid line means a single or double bond.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP569396 | 1996-01-17 | ||
JP8/5693 | 1996-01-17 | ||
PCT/JP1997/000065 WO1997025986A1 (en) | 1996-01-17 | 1997-01-16 | Intimal thickening inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97117350A true RU97117350A (en) | 1999-07-20 |
RU2145852C1 RU2145852C1 (en) | 2000-02-27 |
Family
ID=11618190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU97117350A RU2145852C1 (en) | 1996-01-17 | 1997-01-16 | Inhibitor of intima hypertrophy, use of hydroxyindole derivative for synthesis of inhibitor of intima hypertrophy, compositions for inhibition of intima hypertrophy, method of prophylaxis and treatment of intima hypertrophy |
Country Status (12)
Country | Link |
---|---|
US (1) | US5977130A (en) |
EP (1) | EP0815859B1 (en) |
KR (1) | KR100264807B1 (en) |
AT (1) | ATE243034T1 (en) |
AU (1) | AU708167B2 (en) |
CA (1) | CA2214759C (en) |
DE (1) | DE69722858T2 (en) |
ES (1) | ES2201266T3 (en) |
HU (1) | HUP9800757A3 (en) |
NO (1) | NO315688B1 (en) |
RU (1) | RU2145852C1 (en) |
WO (1) | WO1997025986A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147106A (en) | 1997-08-20 | 2000-11-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US6906093B2 (en) | 1995-06-07 | 2005-06-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6531502B1 (en) | 1998-01-21 | 2003-03-11 | Sugen, Inc. | 3-Methylidenyl-2-indolinone modulators of protein kinase |
US6828344B1 (en) * | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6569868B2 (en) | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
DE69938258T2 (en) * | 1998-12-17 | 2009-02-26 | F. Hoffmann-La Roche Ag | 4,5-PYRAZINOXINDOLE AS PROTEIN KINASE INHIBITOR |
GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
US6492398B1 (en) | 1999-03-04 | 2002-12-10 | Smithkline Beechman Corporation | Thiazoloindolinone compounds |
US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
UA75054C2 (en) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Substituted in position 6 indolinones, producing and use thereof as medicament |
US6620818B1 (en) | 2000-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Method for reducing the severity of side effects of chemotherapy and/or radiation therapy |
MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
US6706709B2 (en) | 2000-06-02 | 2004-03-16 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
US6599902B2 (en) | 2001-05-30 | 2003-07-29 | Sugen, Inc. | 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
CN1295216C (en) * | 2003-07-04 | 2007-01-17 | 中国人民解放军军事医学科学院毒物药物研究所 | Molindone derivatives and use for preparing antineoplastic medicine thereof |
WO2005018531A2 (en) * | 2003-08-26 | 2005-03-03 | 'chemical Diversity Research Institute', Ltd. | Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof |
WO2006105795A1 (en) * | 2005-04-08 | 2006-10-12 | Leo Pharma A/S | Novel indolinone derivatives |
WO2011032320A1 (en) | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Novel alkene oxindole derivatives |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3413299A (en) * | 1963-07-11 | 1968-11-26 | Upjohn Co | 3', 3'-di-substituted[spiro-indoline-3, 2'-oxiran]-2 ones and derivatives |
US3428649A (en) * | 1968-01-23 | 1969-02-18 | Mcneilab Inc | Oxindole derivatives |
US3725403A (en) * | 1970-10-20 | 1973-04-03 | Squibb & Sons Inc | Benzothiazine derivatives |
US4002749A (en) * | 1975-08-12 | 1977-01-11 | E. R. Squibb & Sons, Inc. | Substituted indolinones |
JPS6229570A (en) * | 1985-07-29 | 1987-02-07 | Kanegafuchi Chem Ind Co Ltd | 3,5-diisopropylbenzylidene heterocyclic compound |
ZA896851B (en) * | 1988-09-14 | 1990-06-27 | Hoffmann La Roche | Use of ace-inhibitors |
ES2110965T3 (en) * | 1989-07-25 | 1998-03-01 | Taiho Pharmaceutical Co Ltd | DERIVED FROM OXOINDOL. |
WO1992007830A2 (en) * | 1990-10-29 | 1992-05-14 | Pfizer Inc. | Oxindole peptide antagonists |
JP3130342B2 (en) * | 1991-10-04 | 2001-01-31 | 日産化学工業株式会社 | Atherosclerotic intimal thickening inhibitor |
FR2694004B1 (en) * | 1992-07-21 | 1994-08-26 | Adir | News 3- (Hydroxybenzylidenyl) -indoline-2-ones and 3- (hydroxybenzylidenyl) -indoline-2-thiones, methods of preparation, and pharmaceutical compositions containing them. |
GB9313638D0 (en) * | 1993-07-01 | 1993-08-18 | Erba Carlo Spa | Arylidene and heteroarylidene oxindole derivatives and process for their preparation |
US5502072A (en) * | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
-
1997
- 1997-01-16 KR KR1019970706431A patent/KR100264807B1/en not_active IP Right Cessation
- 1997-01-16 HU HU9800757A patent/HUP9800757A3/en unknown
- 1997-01-16 US US08/913,237 patent/US5977130A/en not_active Expired - Fee Related
- 1997-01-16 ES ES97900424T patent/ES2201266T3/en not_active Expired - Lifetime
- 1997-01-16 CA CA002214759A patent/CA2214759C/en not_active Expired - Fee Related
- 1997-01-16 RU RU97117350A patent/RU2145852C1/en not_active IP Right Cessation
- 1997-01-16 AU AU13986/97A patent/AU708167B2/en not_active Ceased
- 1997-01-16 WO PCT/JP1997/000065 patent/WO1997025986A1/en active IP Right Grant
- 1997-01-16 DE DE69722858T patent/DE69722858T2/en not_active Expired - Fee Related
- 1997-01-16 EP EP97900424A patent/EP0815859B1/en not_active Expired - Lifetime
- 1997-01-16 AT AT97900424T patent/ATE243034T1/en not_active IP Right Cessation
- 1997-09-16 NO NO19974280A patent/NO315688B1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU97117350A (en) | INTIMA HYPERTROPHY INHIBITOR, OXINDOL DERIVATIVE APPLICATION FOR THE INIMA HYPERTROPHY INHIBITOR INHIBITOR, A COMPOSITION FOR INHIBITING INTIMA HYPERTROPHY, PREVENTION AND TREATMENT HYPERT | |
DK0880508T3 (en) | Quinazoline derivatives as VEGF inhibitors | |
RU2002106503A (en) | METHOD FOR TREATING DISEASES MEDIATED BY OPIOID RECEPTORS | |
RU94036774A (en) | INHIBITION OF PROLIFERATION OF SMOOTH MUSCLE CELLS AND RESTENOSIS | |
RU98106623A (en) | DITIOLANE DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC EFFECT | |
EA200200873A1 (en) | NEW PIPERAZINE DERIVATIVES | |
ES538418A0 (en) | A DERIVATIVE OF INDOL-3-CARBOXAMIDE | |
ATE156804T1 (en) | ETHANOLAMINE DERIVATIVES WITH SYMPATHOMIMETIC AND ANTI-POLLAKIURIA EFFECTS | |
DK0652002T3 (en) | Use of 2-phenyl-3-aroylebenzothiophenes in the manufacture of a drug for inhibiting cartilage degradation | |
RU97115107A (en) | BICYCLIC DERIVATIVES OF ISOTHYOTURES USED IN THERAPY | |
DE69828197D1 (en) | AMID DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDERS OF THE NETWORK | |
DE69330601D1 (en) | SEROTON INERGIC ERGOLIN DERIVATIVES | |
AR007052A1 (en) | A CARBOHYDRATE DERIVATIVE, ITS USE AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT | |
RU99113432A (en) | NEW DERIVATIVES OF PHENANTRIDINIA | |
RU2009148601A (en) | APPLICATION OF INHIBITORS WHERE TO TREAT BONE TISSUE DESTRUCTION | |
DE60232186D1 (en) | CHINOLINE DERIVATIVES, SYNTHESIS METHODS AND MEDICAMENTS CONTAINING SUCH DERIVATIVES | |
RU2000102642A (en) | MEDICAL MEANS AGAINST AloPETIA | |
EA200200379A3 (en) | Pyrimidin-4-one compounds, process for their preparation and pharmaceutical compositions containing them | |
RU2335492C2 (en) | New 5,6-dihydropyridine-2-on compounds applicable as thrombin inhibitors | |
RU93058393A (en) | ETHANOLAMINE DERIVATIVES THAT DISTRIBUTE SYMPATHOMOMETIC AND ANTIPOLAKIURIAL ACTIVITY, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | |
TH19066EX (en) | Method for inhibiting smooth muscle cell proliferation and stenosis | |
GB2316944A (en) | New catechol derivatives | |
ECSP961773A (en) | METHODS TO MINIMIZE LOSS OSEA X-10208 | |
SE0100344D0 (en) | New Use | |
RU2009145803A (en) | APPLICATION OF INHIBITORS WHERE TO TREAT MELANOMA |